Condition: Relapsed Non Hodgkin Lymphoma · Relapsed Adult ALL · Relapsed Pediatric ALL · Sponsor: University of Alberta
Autologous, unselected CD3+ lymphocytes collected from apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ).
This description comes directly from the study's public registry record.
Zack Breckenridge · 7803917687 · zackariah.breckenridge@ahs.ca
Always discuss trial participation with your own doctor first.
| Foothills Medical Centre | Calgary, Alberta, Canada | Not Yet Recruiting |
| Tom Baker Cancer Centre | Calgary, Alberta, Canada | Not Yet Recruiting |
| Alberta Children's Hospital | Calgary, Alberta, Canada | Not Yet Recruiting |
| Cross Cancer Institute | Edmonton, Alberta, Canada | Recruiting |
| Stollery Children's Hospital | Edmonton, Alberta, Canada | Not Yet Recruiting |
| University of Alberta Hospital | Edmonton, Alberta, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03938987